Literature DB >> 26546368

Feasibility of Subxiphoid Anatomic Pulmonary Lobectomy in a Canine Model.

Ming-Ju Hsieh1, Yi-Cheng Wu1, Chi-Ju Yeh2, Chieng-Ying Liu3, Chia-Chuan Liu4, Po-Jen Ko1, Yun-Hen Liu5.   

Abstract

Purpose Transthoracic thoracoscopic approach is the gold standard in surgical treatment for thoracic disease. However, it is associated with significant chronic postoperative wound discomfort. Currently, limited data are available regarding the subxiphoid approach to the thoracic cavity. The present study is aimed to evaluate the performance of a subxiphoid anatomic pulmonary lobectomy (SAPL) in a canine model. Methods The SAPL procedure was performed in 10 beagle dogs using a 3-cm incision over the xiphoid process. After thoracic exploration, SAPL was performed under flexible bronchoscopy guidance. The pulmonary vessel was divided with Ligasure and secured with a suture ligature. The bronchus was divided with endostapler. Surgical outcomes were evaluated by the success of SAPL and operative complications. Results SAPL was successfully completed in 9 animals. One animal required conventional thoracotomy to resuture the pulmonary artery stump. Another animal encountered small middle lobe laceration after SAPL and died at 8 days postoperation due to respiratory distress. Conclusion Subxiphoid anatomic pulmonary lobectomy is technically feasible. Refinement of endoscopic instruments combined with more research evidences may facilitate the development of subxiphoid platform in thoracic surgery.
© The Author(s) 2015.

Entities:  

Keywords:  NOTES; SILS; flexible endoscopy; single-site surgery

Mesh:

Year:  2015        PMID: 26546368     DOI: 10.1177/1553350615615441

Source DB:  PubMed          Journal:  Surg Innov        ISSN: 1553-3506            Impact factor:   2.058


  1 in total

1.  Video-assisted thoracic surgery anatomical lobectomy for a primary lung tumor in a dog.

Authors:  Eiichi Kanai; Noriyuki Matsutani; Ryutaro Hanawa; Satoshi Takagi
Journal:  J Vet Med Sci       Date:  2019-09-18       Impact factor: 1.267

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.